MiR-96 functions as a tumor suppressor gene by targeting NUAK1 in pancreatic cancer

International Journal of Molecular Medicine

Volumn 34, Issue 6, 2014, Pages 1599-1605

  Huang, Xuan ^a,b   Lv, Wei ^c   Zhang, Jian Hua ^c   Lu, Da Lin ^a  

^a WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b NANCHANG UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

MicroRNA 96; Novel (nua) kinase family 1; Pancreatic cancer

Indexed keywords

COMPLEMENTARY DNA; MICRORNA; MICRORNA 96; NUA KINASE FAMILY 1; PROTEIN KINASE; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MIRN96 MICRORNA, HUMAN; NUAK1 PROTEIN, HUMAN; REPRESSOR PROTEIN; TUMOR MARKER;

3' UNTRANSLATED REGION; ALGORITHM; ARTICLE; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR PATHOLOGY; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; CELL MOTION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING;

3' UNTRANSLATED REGIONS; ALGORITHMS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; PANCREATIC NEOPLASMS; PROTEIN KINASES; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84908070453     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1940     Document Type: Article

References (32)

1. Lee RC, Feinbaum RL and Ambros V: The C. elegans heter-ochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854, 1993.
2. Pasquinelli AE, Reinhart BJ, Slack F, et al: Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408: 86-89, 2000.
3. Reinhart BJ, Slack FJ, Basson M, et al: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403: 901-906, 2000.
4. Esteller M: Non-coding RNAs in human disease. Nat Rev Genet 12: 861-874, 2011.
5. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
6. Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Annu Rev Med 60: 167-179, 2009
7. Slack FJ and Weidhaas JB: MicroRNA in cancer prognosis. N Engl J Med 359: 2720-2722, 2008.
8. Yu S, Lu Z, Liu C., et al: miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res 70: 6015-6025, 2010.
9. Suzuki A, Kusakai G, Kishimoto A., et al: Identification of a novel protein kinase mediating Akt survival signaling to the ATM protein. J Biol Chem 278: 48-53, 2003.
10. Suzuki A, Kusakai G, Kishimoto A, et al: ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation. Oncogene 22: 6177-6182, 2003.
11. Suzuki A, Kusakai G, Kishimoto A., et al: Regulation of caspase-6 and FLIP by the AMPK family member ARK5. Oncogene 23: 7067-7075, 2004
12. Kusakai G, Suzuki A, Ogura T., Kaminishi M and Esumi H: Strong association of ARK5 with tumor invasion and metastasis. J Exp Clin Cancer Res 23: 263-268, 2004
13. Kusakai G, Suzuki A, Ogura T., et al: ARK5 expression in colorectal cancer and its implications for tumor progression. Am J Pathol 164: 987-995, 2004
14. Suzuki A, Lu J, Kusakai G., Kishimoto A, Ogura T and Esumi H: ARK5 is a tumor invasion-associated factor downstream of Akt signaling. Mol Cell Biol 24: 3526-3535, 2004
15. Chen P, Li K, Liang Y., Li L and Zhu X: High NUAK1 expression correlates with poor prognosis and involved in NSCLC cells migration and invasion. Exp Lung Res 39: 9-17, 2013.
16. Bell RE, Khaled M, Netanely D., et al: Transcription factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1. J Invest Dermatol 134: 441-451, 2014.
17. Lu S, Niu N, Guo H., et al: ARK5 promotes glioma cell invasion, and its elevated expression is correlated with poor clinical outcome. Eur J Cancer 49: 752-763, 2013.
18. Chang XZ, Yu J, Liu H.Y., Dong RH and Cao XC: ARK5 is associated with the invasive and metastatic potential of human breast cancer cells. J Cancer Res Clin Oncol 138: 247-254, 2012.
19. Cui J, Yu Y, Lu G.F., et al: Overexpression of ARK5 is associated with poor prognosis in hepatocellular carcinoma. Tumour Biol 34: 1913-1918, 2013.
20. Luo XG, Zou JN, Wang S.Z., Zhang TC and Xi T: Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells. IUBMB Life 62: 194-199, 2010.
21. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
22. Sant M, Allemani C, Santaquilani M., et al: EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 45: 931-991, 2009.
23. Hidalgo M: Pancreatic cancer. N Engl J Med 362: 1605-1617, 2010.
24. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19: 3210-3218, 2001.
25. Hennessy BT, Hanrahan EO and Daly PA: Non-Hodgkin lymphoma: an update. Lancet Oncol 5: 341-353, 2004.
26. Ekstrand AI, Jönsson M, Lindblom A., Borg A and Nilbert M: Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Fam Cancer 9: 125-129, 2010.
27. Li B, Tsao SW, Li Y.Y., et al: Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway. Int J Cancer 125: 2576-2585, 2009.
28. Ohta T, Isobe M, Takahashi T., Saitoh-Sekiguchi M, Motoyama T and Kurachi H: The Akt and ERK activation by platinum-based chemotherapy in ovarian cancer is associated with favorable patient outcome. Anticancer Res 29: 4639-4647, 2009.
29. Simon PO J.r., McDunn JE, Kashiwagi H, et al: Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma. Int J Cancer 125: 942-951, 2009.
30. Lee EJ, Gusev Y, Jiang J., et al: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 120: 1046-1054, 2007.
31. Dillhoff M, Liu J, Frankel W., Croce C and Bloomston M: MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 12: 2171-2176, 2008.
32. Ji Q, Hao X, Zhang M., et al: MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 4: e6816, 2009.